Attacking Solid Tumors

Solid Tumors

Does enough drug penetrate your tumor? In solid tumors, only a small percentage may reach your tumor cells.

Getting the right drug into the right place, safely and effectively enables better immunotherapy outcomes in solid tumors.

Attacking Solid Tumors

Solid Tumors

Developing immunotherapy treatments for liver and pancreatic tumors using our novel delivery technology.

Attacking Solid Tumors

Solid Tumors

Our unique combination of investigational immuno-oncology agents and FDA cleared delivery technology may help patients face the toughest clinical cancer challenges.

Our Story
Our Passion
Our Approach

We are developing investigational treatments to attack liver metastases and pancreatic solid tumors and stimulate the immune system by delivering a combination of immunotherapies directly to the site of disease.

TriSalus Investigational Focus

Learn more about our approach by clicking on any of the circles in the diagram above. 

TriSalus multi-pronged approach which combines immunomodulation therapy or other tumor killing agents with our FDA cleared intravascular regional drug delivery system is under investigation for the treatment of liver metastases, pancreatic cancer, and other solid tumors.

Targeted Therapeutic

We believe that a comprehensive approach is needed for liver and pancreatic tumors. Our strategy involves studying optimal delivery of therapeutics into high pressure solid tumors, while using immunomodulatory approaches with the goal to help enable deeper responses to immunotherapies designed to target cancer cells. Our focus is on addressing critical issues that limit immunotherapy success in the liver and pancreas.


Leveraging our proprietary PEDD™ approach for the regional delivery of investigational SD-101, a TLR9 agonist, currently being studied for the potential to convert unresponsive tumors to responsive tumors by converting immunosuppressor cells into immunostimulant cells.

Regional Tumor-Directed Delivery

Our unique PEDD™ approach is able to perfuse a therapeutic more uniformly across the vascular bed supplying the tumor, with the potential of improving response.1,2,*


  1. Data on File, Porcine Model, TriSalus Life Sciences 2020
  2. Titano, J.J., et al. Cardiovasc Intervent Radiol. 2019;42:560-568.

* Titano et al: A small, retrospective, single-center study included 88 treatment-naive patients with solitary HCC tumors <6.5 cm who underwent treatment utilizing either SIS (n = 18) or standard EH microcatheters (n = 70). Twenty-three patients (5 SIS, 18 EH) received a liver transplant during the study, with 1 SIS and 6 EH patients excluded from the tumor necrosis analysis for receiving subsequent therapies prior to transplant. A pathologist performed a blinded review of the liver explant specimens to assess tumor necrosis and treatment distribution. Pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in SIS explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002).

Patients and Caregivers

We start with clinical experts who define the barriers limiting therapy effectiveness for liver and pancreatic tumors. Our mission is to put the right drugs and the right devices into the hands of cancer treatment experts to enable new treatment approaches for liver, pancreatic, and other tumors.


Latest News

June 22, 2022
TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors
May 10, 2022
TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma